Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397520 | 0.92 | L3MBTL1 (0.48) | L3MBTL1HRH3ALDH1A1KDM4ERORC | |
| SCHEMBL4289837 | 0.80 | CHKA (0.55) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL3397376 | 0.80 | GFER (0.51) | ALDH1A1KDM4EMEN1KMT2AGPR183 | |
| SCHEMBL2106701 | 0.78 | ALDH1A1 (0.46) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17422248 | 0.78 | MEN1 (0.50) | ALDH1A1KDM4EMEN1KMT2AALOX15 | |
| SCHEMBL1427472 | 0.76 | ALDH1A1 (0.49) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4287610 | 0.76 | KDM4E (0.39) | HRH3ALDH1A1KDM4ETDP1 | |
| SCHEMBL2574046 | 0.74 | KMT2A (0.42) | ALDH1A1KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL5539795 | 0.74 | HRH3 (0.53) | L3MBTL1HRH3ALDH1A1KDM4ERORC | |
| SCHEMBL1927730 | 0.74 | HRH3 (0.76) | L3MBTL1HRH3ALDH1A1RORCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | L3MBTL1 3749/4885HRH3 2278/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.